Despite the high variability of structures from marketed drugs, molecules with biological activity have certain features in common. We have analysed these complex drug patterns to build up an expert system, which is able to discriminate between drugs and non-drugs:

MolScore-Drugs near 0:                             => lowest predicted probability

MolScore-Drugs near 1:
        
=> highest predicted probability
               attractive ADME-profile

MolScore-Drugs

    The expert system is based on a variety of reliable models. Structure-activity relationships allow the estimation of useful drug-like chemical space. Structure-property relationships which are derived from our in-house ADME/Tox-database are applied to predict ADMET properties and to identify potential risks in order to reduce clinical failures.


Download
product
description
(pdf)
 


MolScore-Drugs
measures the probability
of a compound
to become a drug and is defined as a value between
0 and 1.
 


Drug Pattern
can contain information about structural composition, chemical topology, ADME characteristics, toxicity-profile, synthetic availability, bioavailability, etc.
   Further Links:
Drug design
Drug discovery
Drug development
Cheminformatic
software

ADME
Pharmacokinetics
Bioavailability
Computational chemistry
Molecular
modeling

Clinical trials
Preclinical
Research

    The results of MolScore-Drugs can easily be integrated into customer’s database. This will allow virtual screening, ranking and selecting compounds from external suppliers before they have to be purchased, see selecting compounds. MolScore-Drugs can be used to detect future blockbusters, see detecting blockbusters. All models which have been integrated into the expert system have been successfully validated with independent data sets.

    MolScore-Drugs helps to identify and prioritise promising drug candidates with the maximum possibility of success in human trials, see lead prioritisation and selection.

All compounds with a valid chemical structure can be analysed; even before a compound has to be synthesised. The threshold (boundary between drugs and non-drugs) can be set by the customer. All results are supplied in an SDF-file. These results can be imported into other commercial software to actually see on screen (visualisation), for data analysis or for selection of compounds with additional filters.


MolScore-Drugs

    Expert system to identify promising drug candidates
                                                                   ==> Lead selection
                                                                   ==> Prioritisation of drug candidates



© Copyright 2004-2017 PharmaInformatic Boomgaarden. All rights reserved.           Site map           Contact         Terms of Use         Imprint        



 

 Recent News:

PharmaInformatic and
UNIZYME
Laboratories
sign
cooperation agreement:

Selection and prioritisation
of
lead compounds
for treatment of
inflammatory diseases
based on estimated oral bioavailability in humans with IMPACT-F.
(more)